Erudio Bio, Inc.

posted: 28-Oct-2026 & updated: 28-Oct-2026

Prepared by Sunghee Yun (Co-Founder & CTO) · personal study notes

The Six Biosimilar Bills

Four Senate bills and two House companions, all in the 119th Congress, aimed at the gap between what the 2010 BPCIA promised and what biosimilars actually delivered.

How to read a bill number

“S.” is a Senate bill, “H.R.” a House bill. A bill must pass both chambers in identical text, which is why companion bills are introduced in parallel — the same proposal started simultaneously on both sides to save time. Health bills are referred to the Senate HELP committee (Health, Education, Labor and Pensions); the House counterpart is Energy and Commerce. An antitrust bill goes to Judiciary instead.

A Congress runs two years. The 119th runs January 2025 to January 2027, and anything not passed by the end of it dies and must be reintroduced from scratch in the next one. That is why several of these bills appear “in their third Congress” — the proposal has been made repeatedly and has repeatedly run out of clock.

The bills

Statuses as of July 2026 — re-verify before citing, since committee action moves quickly.

Bill Name Sponsors What it does Status What it changes
S.1414 / H.R. 9661 Expedited Access to Biosimilars Act Senate: Paul (R-KY), Lee (R-UT), Hassan (D-NH). House (introduced 15 July 2026): Langworthy (R-NY), Schrier (D-WA) Removes the default requirement that a biosimilar applicant run a comparative clinical efficacy study; FDA keeps the authority to require one case by case Ordered reported by HELP, 22 July 2026 The testing burden. If clinical trials are no longer the default, analytical evidence of equivalence becomes the whole case — which raises the standard demanded of analytical methods
S.1954 / H.R. 5526 Biosimilar Red Tape Elimination Act Senate: Lee (R-UT), Luján (D-NM), Paul, Hassan, Schmitt, Ossoff. House (September 2025): Pfluger (R-TX), Landsman (D-OH) Deems every FDA-licensed biosimilar interchangeable with its reference product, so pharmacists can substitute automatically; no switching studies required. Preserves exclusivity already earned by first interchangeables Introduced in three consecutive Congresses; this time ordered reported favourably by HELP 17 June 2026 and placed on the Senate calendar 27 July Substitution friction — the barrier that kept pharmacists from swapping in the Humira era. Raises the stakes on equivalence: if any approved biosimilar can be auto-substituted, “are these two truly the same?” becomes a question asked at every counter
S.1096 Preserve Access to Affordable Generics and Biosimilars Act Klobuchar (D-MN), Grassley (R-IA) + eight cosponsors (5 D, 3 R) Bans pay-for-delay: a settlement in which the brand gives a generic or biosimilar maker anything of value — cash, or a promise not to launch an authorised generic — in exchange for delayed entry is presumed anticompetitive. FTC enforces Ordered reported by Judiciary, 3 April 2025 — earliest to clear committee; earlier versions passed the Senate and died in the House Anticompetitive settlements. Antitrust, not science. Explains part of why Humira biosimilars were held off until 2023: AbbVie settled with every challenger on a 2023 entry date
S.3510 Biosimilar Inspection Modernization Act of 2025 Budd (R-NC), Hassan (D-NH) Expands remote regulatory assessments, convenes a meeting on mutual recognition agreements with foreign regulators, requires an FDA plan on domestic inspections Has not moved Inspection logistics. Peripheral to the evidence question

The shape of the whole set

One line to hold onto: the bills attack three different things — testing burden (S.1414), substitution friction (S.1954) and anticompetitive settlements (S.1096) — plus inspections (S.3510). Often cited alongside them, but not bills: FDA’s 29 October 2025 announcement on dropping clinical efficacy studies for some biosimilars, the Langworthy/Schrier press release, and David Lim’s Politico piece of 21 July 2026 on Hill momentum.